Prevalence and patterns of inflammatory arthritis and fibromyalgia in inflammatory bowel disease: A single-center, cross-sectional study

Hampannavar, Mahesh R; Naidu, Gsrsnk; Sharma, Vishal; Sinha, Anindita; Dhir, Varun; Sharma, Shefali; Sharma, Aman; Jain, Sanjay

doi:10.1007/s12664-023-01406-z

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBD is wellrecognized to have many extraintestinal manifestations. Certain musculoskeletal manifestations are well recognized with IBD including arthritis (peripheral and axial), osteoporosis and fibromyalgia [7,8]. IBD is a chronic inflammatory disease and may also predispose to osteonecrosis with or without concomitant use of corticosteroid therapies [9] .…”

Section: Introductionmentioning

confidence: 99%

Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis

Bhayana,

Sharma,

Sharma

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

Self Cite

View full text Add to dashboard Cite

Background The relationship of inflammatory bowel disease (IBD) with osteonecrosis or avascular necrosis (AVN) is uncertain. Methods Systematic review to estimate the frequency of osteonecrosis in IBD was performed. Electronic databases were searched on 12 December 2022 to identify relevant studies. We planned to estimate the pooled prevalence of AVN in IBD, the risk in IBD when compared to the healthy population (without any chronic disease), and the impact of steroid use on osteonecrosis (IBD with and without steroid use). The risk of Bias was assessed with the Joanna Briggs Institute appraisal tool. Results Fifteen studies including 105 154 individuals were included. The pooled rate AVN was 10.39 per 1000 patients (95% confidence interval, 4.44–24.11, I2 = 97%). Subgroup analysis suggested that the prevalence was lower in larger studies (>1000 participants) at 3.10, 1.07; 8.98, I2 = 98% versus 21.03, 8.69; 50.01, I2 = 83%. The use of steroids did not seem to increase the risk of osteonecrosis in the included studies (pooled odds ratio: 1.88, 0.55–6.41, I2 = 39%). The systematic review was limited by the absence of comparison with the control population free of chronic disease. Conclusion IBD may be associated with a risk of osteonecrosis. Future studies should assess the risk in comparison to the healthy population and the impact of disease activity and IBD therapies on the risk.

show abstract

Section: Introductionmentioning

confidence: 99%